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Abstract
CD4+ T cells are critical for effective immune responses against HIV, but they are also the main cell type targeted by the virus. To investigate
the key factors that could protect these cells from infection, we evaluated the capacity of HIV gp120-specific human CD4+ T cells to produce
chemokines that inhibit HIV and determined their contribution in suppressing infection in the cells. Antigen stimulation of the CD4+ T cells
elicited production of high amounts of CCR5 chemokines MIP-1α (CCL3), MIP-1β (CCL4), and RANTES (CCL5). Production of these CCR5
ligands was more readily and reproducibly detected than that of IFN-γ or IL-2. Importantly, in association with secretion of the CCR5 ligands,
antigen stimulation made these CD4+ T cells more resistant to CCR5-tropic HIV-1. Conversely, in the absence of antigen stimulation, the cells
were readily infected by the virus, and after infection, their capacity to produce MIP-1β and IFN-γ rapidly declined. Thus, vaccines that trigger
HIV-specific CD4+ T cells to elicit robust and rapid production of anti-viral chemokines would be advantageous. Such responses would protect
virus-specific CD4+ T cells from HIV infection and preserve their critical functions in mounting and maintaining long-lasting immunity against the
virus.
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Virus-specific CD4+ T cells are a critical component of
immune responses against HIV, but these cells are also the
prime targets for HIV infection. Indeed, HIV-specific CD4+ T
cells have been reported to be preferentially infected with the
virus as compared to CD4+ T cells specific for other antigens
(Douek et al., 2002), and they were depleted early during the
primary HIV infection due to apoptosis and/or cytopathic
effects of HIV infection (Brenchley et al., 2006; Malhotra et al.,⁎ Corresponding author. VA Medical Center, 423 E. 23rd St. Room 18-124
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doi:10.1016/j.virol.2007.07.0312003; Yue et al., 2005; Zaunders et al., 2005). In the SIV model,
Staprans et al. (2004) showed that increased CD4+ T cell
proliferation was associated with enhanced levels of virus
replication and pathogenesis in rhesus macaques that were
vaccinated prior to SIV challenge. Maier et al. (2000) also
presented evidence that activation of CD4+ T cells by super-
antigens leads to up-regulation of the surface expression of the
chemokine receptors CCR5 and CXCR4, rendering the cells
highly susceptible to HIV infection. Hence, there are concerns
that stimulating and expanding HIV-specific CD4+ T cells, by
vaccination for example, may supply more target cells for the
virus and increase the host susceptibility to HIV infection.
Nevertheless, not all of virus-specific CD4+ T cells in HIV-
infected subjects are depleted and only b10% are infected by
the virus (Douek et al., 2002; Mattapallil et al., 2005). Our
earlier study demonstrated that CD4+ T cells specific for HIV
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peripheral blood of each of the HIV-infected subjects studied
(Cohen et al., 2003). Notably, a proportion of these cells
remained uninfected and could be propagated readily by antigen
stimulation in vitro. It is clear that a fraction of HIV-specific
CD4+ T cells are able to escape from or resist HIV infection,
although the mechanisms contributing to their virus-free
condition are not yet known.
Previous studies have shown that, in addition to their
traditional roles of providing help to virus-specific CD8+ T cells
and B cells, CD4+ T cells can also mediate direct anti-viral
functions through secretion of cytokines and chemokines that
block or suppress HIV infection (Abdelwahab et al., 2003;
Norris et al., 2004; Robbins et al., 1998; Saha et al., 1998).
Some CD4+ T cells have also been shown to mediate cytolysis
of virus-infected cells (Norris et al., 2004, 2001). Analyses of
immortalized T cell clones generated from HIV-infected
patients with different clinical profiles demonstrated that
CD4+ T cells from non-progressors secreted high levels of
RANTES, MIP-1α, and MIP-1β, and were resistant to infection
by CCR5-tropic HIV-1, while CD4+ T cells from AIDS patients
were deficient in the production of these CC chemokines and
were readily infected by the virus (Saha et al., 1998). HIV-
specific CD4+ T cells from exposed uninfected subjects
expressing the wild type CCR5 allele also secreted high levels
of CC-chemokines with potent anti-viral activities upon antigen
stimulation (Furci et al., 1997). Nevertheless, it is not known to
what extent the CC chemokine production by these CD4+ T
cells confers protection against HIV.
While many studies have demonstrated that CD8+ T cells,
natural killer cells, and macrophages are among the different
immune cells that can be stimulated to produce high levels of
the CC chemokines RANTES, MIP-1α, and MIP-1β(Bernstein
et al., 2004; Cocchi et al., 1995; Fehniger et al., 1998; Oliva et
al., 1998; Verani et al., 1997), limited information is available
regarding the capacity of antigen-specific CD4+ T cells to
produce anti-HIV chemokines and protect themselves against
the virus. A previous study of an influenza virus-specific CD4+
cytolytic T cell line demonstrated that antigen stimulation led to
suppression of CCR5-tropic HIV infection in these CD4+ Tcells
and that the suppressive activity was mediated primarily by CC
chemokines produced in the culture (Robbins et al., 1998).
These chemokines inhibited HIV-1 entry not only by sterically
blocking the CCR5 receptors but also by down-regulating
CCR5 cell surface expression. Whether HIV-specific CD4+ T
cells generated during infection can exhibit a similar anti-HIV
function has not been determined. Since the numbers of HIV-
specific CD4 Tcells are usually very low in the peripheral blood
ex vivo from HIV-infected subjects, we had previously
expanded these cells by 3 to 4 rounds of antigen stimulation
and generated short-term primary lines (Cohen et al., 2003). In
this study, two CD4+ T cell lines recognizing epitopes in the C1
and C2 regions of HIV envelope gp120 (PS01 and PS02) were
examined. These cell lines were generated previously from
PBMC of HIV-infected subjects who are CCR5 Δ32 hetero-
zygotes and maintain their virus loads below 5000 copies/ml
without anti-retroviral therapy. The cells have been shown toproduce IFN-γ upon stimulation with their cognate antigens
(Cohen et al., 2003), but their anti-viral activities have not been
investigated. The present study reports the capacity of these
gp120-specific CD4+ T cells to secrete high amounts of CCR5
chemokines in response to stimulation with their cognate
antigens, the role of these chemokines in in vitro protection
against HIV challenge, and the effect of HIV infection on
production of IFN-γ and the CCR5 ligand MIP-1β.
Results
HIV gp120-specific CD4+ T cell lines produce IFN-γ and
CCR5 ligands upon antigen stimulation
This study evaluated whether HIV-specific CD4+ T cells
could produce anti-viral factors and protect themselves from
HIV infection. Considering that the vast majority of primary
HIV-1 isolates worldwide are CCR5-tropic and the viruses
transmitted from one subject to another are mainly CCR5-tropic
(Hladik et al., 2007; Li et al., 2005a, 2006), we focused our
analyses on the CC chemokines that are ligands for the CCR5
receptor and that are potent inhibitors of CCR5-tropic viruses,
i.e. MIP-1α (CCL3), MIP-1β (CCL4), and RANTES (CCL5).
In addition, we measured production of IFN-γ and IL-2, two
cytokines commonly tested to measure antigen-specific T cell
responses. Two primary CD4+ T cell lines (PS01 and PS02)
recognizing distinct epitopes in the C1 and C2 regions of HIV
envelope gp120 were tested (Cohen et al., 2003). These lines
were expanded by repeated stimulation with gp120-pulsed
antigen-presenting cells and maintained as short-term cultures
(for b10 weeks) in the presence of IL-2.
Intracellular staining assays showed that both the PS01 and
the PS02 cell lines produced IFN-γ, IL-2, and MIP-1β in
response to their respective gp120 peptides, pC1a and pC2. Dot
plots from one representative experiment are shown in Fig. 1. In
both cell lines, MIP-1β responses were consistently more robust
than IFN-γ or IL-2 responses. From multiple experiments with
different stocks of the cell lines, the percentages of MIP-1β
producers reached 8–25% (mean 16%) for PS01 and 44–97%
(mean 71%) for PS02, while the percentages of IFN-γ
producers were 5–14% (mean 12%) for PS01 and 3–60%
(mean 24%) for PS02. These responses were specific, as no
response was detected when the cells were treated with an
irrelevant gp120 peptide control. By comparison, the IL-2
responses were barely detectable; 1.6–2.9% (mean 2.3%) of
PS01 cells and only 0.06–0.4% (mean 0.25%) of PS02 cells
produced this cytokine. The low IL-2 production may be due to
the culturing conditions which include exogenous IL-2. Never-
theless, these data are consistent with a previous report showing
that in PBMCs from healthy subjects with recall responses to
tetanus toxoid, the production of CCR5 ligands was much more
readily detectable than that of IFN-γ while IL-2 secretion was
the poorest (Sun et al., 2004).
When the supernatants from these T cell cultures were tested
by ELISA, we readily detected the presence of the CCR5
ligands RANTES, MIP-1α, and MIP-1β, but not of MDC
(macrophage-derived chemokine or CCL22), which inhibits
Fig. 1. HIV gp120-specific CD4+ Tcells produce IFN-γ andMIP-1β after antigen stimulation. CD4+ Tcell lines PS01 (A) and PS02 (B), which are specific for epitopes in the C1 and C2 regions of gp120, were stimulated
for 6 h with the relevant peptides (pC1a or pC2), control peptide, or no antigen. MAb staining was then performed to detect CD4 (not shown), CD3, IL-2, and IFN-γ or MIP-1β. The frequencies of responding CD4+ T
cells were determined by flow cytometry. Top panels are dot plots showing CD3 and MIP-1β; the bottom panels are dot plots showing IL-2 and IFN-γ. Background surface fluorescence was determined from isotype-













Fig. 2. Secretion of CCR5 ligands by CD4+ T cells after antigen stimulation.
CD4+ T cell lines PS01 and PS02 were stimulated with peptides pC1a and pC2,
respectively, and cultured for up to 1 month in the presence of IL-2. Culture
supernatants were collected and replaced with fresh medium on the designated
days. The levels of RANTES, MIP-1α, MIP-1β, and MDC in the supernatants
were determined by ELISA. Representative data from one of two experiments
are shown.
Fig. 3. Antigen stimulation renders gp120-specific CD4+ T cells more resistant
to HIV infection. T cells were treated with peptide pC2 (solid bars) or untreated
(open bars) for 6 h, and then infected with varying doses of BX08: (A) 7.5×106
v-RNA copies/ml, (B) 7.5×105 v-RNA copies/ml, and (C) 7.5×104 v-RNA
copies/ml. The levels of p24 in the culture supernatants on the designated days
were measured by ELISA.
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secretion of these chemokines was sustained in the PS01 cells
for N20 days, while the PS02 cells secreted high levels of these
CCR5 ligands only within the first 1–3 days after antigen
stimulation. These data clearly show distinct patterns of
chemokine production by these two cell lines. While the reason
for this difference is not known, the PS01 line contained a small,
but consistently detectable, fraction of antigen-specific CD4+ T
cells that produced both IFN-γ and IL-2. These multifunctional
CD4+ T cells might produce additional cytokines such as TNF-
α that up-regulate and sustain production of CCR5 ligands
(Brice et al., 2000; Hornung et al., 2000). The PS02 cell line, on
the other hand, appeared to contain mostly MIP-1β-producing
cells, with few IFN-γ-producing cells and no IL-2-producing
cells (Fig. 1).
CC-chemokine production is associated with HIV-suppressive
activity
To directly evaluate anti-HIVactivities of the gp120-specific
CD4+ T cells, we tested the CD4+ T cell line PS02 that
consistently had a high number of CC-chemokine producers
upon antigen stimulation but could also be cultured without
detectable chemokine secretion in the absence of antigen. PS02
cells were stimulated with the specific gp120 peptide for 6 h and
then infected with a CCR5-tropic primary HIV-1 isolate BX08.
For comparison, a parallel culture of unstimulated cells was also
infected with the same virus. Both cultures were maintained in
medium containing IL-2 for up to 10 days. Virus infection was
monitored by measuring p24 in the supernatants with ELISA.Fig. 3A shows that antigen stimulation suppressed infection
with BX08 virus at 7.5×106 v-RNA copies/ml (equivalent to
100 ng p24/ml), especially at the earlier time points. When one
or two log lower doses of virus were used, the suppression was
nearly complete throughout the observation period (Figs. 3B–
C). Similar results were observed when p24+ cells were detected
in the cultures by flow cytometry (Fig. 4A). During this
observation period (6 days), the cell viability was similar in both
the antigen-stimulated and the unstimulated cultures. The PS02
cell line had no antigen-specific cytolytic activity (Fig. 4D).
Rather, the virus-suppressive activity was associated with
induction of IFN-γ and MIP-1β in the CD4+ T cells within
6 h after gp120 peptide stimulation (Figs. 4B and C).
Interestingly, IFN-γ production waned quickly, such that no
IFN-γ+ cells were detected above background by day 6. In
contrast, MIP-1β production was stable through day 4 and
Fig. 4. Suppression of HIV replication in gp120 peptide-stimulated CD4+ T cells correlates with MIP-1β production. (A) PS02 CD4+ T cells were stimulated for 6 h
with peptide pC2 or left untreated, and exposed 24 h to infectious BX08 (100 ng p24/ml). The cells were then washed and incubated for up to 6 days. On the designated
days, the cells were harvested and fixed. MAb staining and flow cytometric analyses were done on all cells concurrently to detect the fractions of CD4+ T cells bearing
intracellular p24. PS02 cells that were not infected with virus were used as negative controls. Mean and standard deviation from duplicate wells are presented. (B and
C) Parallel cultures of uninfected PS02 cells were also set up in order to monitor IFN-γ and MIP-1β production during the observation period. The cells were treated
for 6 h with peptide pC2 or with medium alone. A fraction of the cells were harvested and fixed immediately (day 0), while the rest were cultured for up to 6 days. On
days 2, 4, and 6, additional fractions of the cells were harvested and fixed. Brefeldin Awas added 4 h prior to fixing. Intracellular cytokine staining was done on all cells
at the same time. The percentages of CD4+ T cells producing IFN-γ or MIP-1β were determined by flow cytometry. Data are representative of three independent
experiments. (D) Cytolytic activity of PS02 cells was assessed in the standard 51Cr-release assay. Autologous B lymphoblastoid cells treated with peptide pC2, control
peptide, or no peptide were used as target cells and incubated for 18 h with PS02 cells at the designated effector/target (E/T) ratios.
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consistent with the data in Fig. 2 showing that CC chemokines
were secreted by PS02 cells for 1–3 days after antigen
stimulation.
Subsequently, we examined whether suppression of HIV
infection was mediated by the CC-chemokines secreted by the
CD4+ T cells. PHA-treated PBMCs from an HIV-seronegative
donor were infected with CCR5-tropic HIV-1 BaL, in the
presence of the CD4+ Tcell supernatants which were pre-treatedwith either a mixture of blocking Abs to RANTES, MIP-1α,
MIP-1β, and MDC, or with irrelevant control Abs (Fig. 5).
Addition of the cell supernatant pretreated with control Abs
suppressed virus infection, and the suppressive effects were
eliminated by pretreatment with anti-chemokine Abs. Medium
that contained no T cell supernatant and were treated with Abs
was included as negative controls and showed no virus-
suppressive activity. Since the CD4+ T cell supernatant
contained RANTES, MIP-1α and MIP-1β (Fig. 2), these
Fig. 5. Chemokines secreted by gp120-specific CD4+ T cells mediate suppression of HIV infection. Supernatant collected from the culture of gp120-specific CD4+ T
cells after antigen stimulation (left graph) or medium containing no supernatant (right graph) was treated with a combination of antibodies against MIP-1α, MIP-1β,
RANTES, and MDC (anti-CK Abs) or with control antibodies. The treated supernatants or medium were added to mitogen-blasted PBMCs infected with HIV-1 BaL at
a final concentration of 25% (a 1:4 dilution). Comparable results were obtained with T cell supernatant diluted 1:2 (data not shown). The levels of p24 in the cultures
were monitored by ELISA. p24 levels in virus-infected PBMCs that were left untreated (medium only) were also assessed for comparison.
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here was primarily due to these CC-chemokines. Of note, the
addition of anti-chemokine Abs enhanced infection above that
seen in PBMCs cultured with virus alone. This enhancing effect
is most likely due to the blocking of CC-chemokines producedFig. 6. Upon peptide stimulation, gp120-specific CD4+ T cells express IFN-γ and MIP
CD4+ T cell line PS02 was treated for 6 h with specific peptide pC2 (solid black line),
assessed for surface expression of CCR5 by CCR5-specific mAb stained and flow cyto
determine background fluorescence (dotted gray line). (B) Parallel cultures of cells w
stained intracellularly with mAbs to IFN-γ (left panel) or MIP-1β (right panel). T
representative of two separate experiments.by mitogen-stimulated PBMCs by the Abs (Furci et al., 1997;
Kinter et al., 1996; Sun et al., 2004). The same supernatants
were also tested for suppressive activity against CXCR4-tropic
HIV-1IIIB, but the levels of suppression detected were low and
inconsistent (data not shown).-1β but chemokine receptors CCR5 are not down-regulated. (A) Gp120-specific
irrelevant peptide control (dotted black line), or no peptide (solid gray line), and
metric analysis. Cells stained with isotype-matched irrelevant mAb were used to
ere similarly treated with peptide pC2, control peptide, or no peptide, and then
he percentages of positive cells were determined by flow cytometry. Data are
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down-regulation
The binding of chemokines to their G protein-coupled receptors
causes receptor internalization that can down-regulate the surface
expression of these receptors (Fernandis et al., 2002; Mack et al.,
1998; Signoret et al., 2005). To determine whether the secretion of
CC-chemokines upon antigen stimulation of gp120-specific CD4+
T cells is accompanied by down-regulation of CCR5 from the cell
surface, we measured the levels of CCR5 expression on the surface
of PS02 cells following treatment with the relevant gp120 peptide,
control peptide, or medium alone. The flow cytometry data
demonstrate that after a 6 h treatment with the antigenic gp120
peptide, the CCR5 levels on the CD4+ Tcell surface did not change
(Fig. 6A). Surface levels of CD4+ also remained unchanged (data
not shown). At this time point, significant percentages of the cells in
the culture produced MIP-1β and IFN-γ (Fig. 6B). These data
indicate that while antigen activation of gp120-specific CD4+ T
cells elicits production of CC-chemokines that suppress HIV
infection, the suppressive activity is not likely due to down-
regulation of the chemokine receptor CCR5.
Production of IFN-γ and MIP-1β is impaired by HIV infection
Gp120-specific CD4+ T cells were capable of suppressing
HIV infection, but this anti-viral activity was only achieved if
the cells were first stimulated by their specific gp120 peptides to
produce CC-chemokines. The resistance to infection was,
however, incomplete; when the cells were exposed to relatively
high doses of virus, virus replication still occurred at low levels.
To assess if the gp120-specific CD4+ T cells infected with HIV
were able to respond to their specific antigens, PS02 cells were
first infected with CCR5-tropic HIV-1 BX-08 for 0 to 5 days,
and then stimulated with the specific gp120 peptide at different
time points. Intracellular staining assays were performed to
detect cells expressing p24 and IFN-γ or MIP-1β. As expected,
very little infection (b5%) was observed 24 h after infection, but
almost all of the cells were p24+ by days 4–5 (Fig. 7). On day 1,
when a few cells were positive for p24, the CD4+ T cells were
responsive to gp120 peptides, and the frequency of CD4+ T
cells producing IFN-γ or MIP-1β in the virus-infected culture
was comparable to the frequency of CD4+ responders in the
uninfected cultures. However, from day 2 to day 5, as the
number of p24+ cells and intensity of p24 staining in all cells
rose, the frequency of cells responsive to gp120 peptides
declined, almost to the background level by day 5. In a parallel
uninfected culture, the numbers of cells that produced IFN-γ or
MIP-1β in response to gp120 peptide were relatively stable
from day 0 to day 5. These results demonstrate deleteriousFig. 7. HIV infection impairs the production of IFN-γ and MIP-1β by gp120-specific
for 4 or 5 days. On the designated days, a fraction of the cells in each culture were tre
The background fluorescence for p24 was based on cells collected on day 0 and on
stained for IFN-γ or MIP-1β and used to determine the cut-off for the respective cyt
percentages of CD4 T cells positive for p24 and IFN-γ or MIP-1β. (A) Dot plots of
(B) Dot plots of HIV-infected and uninfected PS02 cells stained with mAbs to p24 and
(top graphs) or p24 and MIP-1β (bottom graphs) over time in HIV-infected and unieffects of HIV infection on the virus-specific CD4+ T cells and
particularly on the anti-viral functions of these cells.
Discussion
This study provides the first evidence that antigen stimula-
tion of HIV-specific CD4+ T cells protected these cells against
the subsequent challenge by CCR5-tropic HIV-1, and that the
virus-inhibitory activity was associated with the secretion of CC
chemokines. Prior to antigen stimulation, the cells produced
undetectable or low amounts of these chemokines and were
readily infected by HIV. Within hours after antigen stimulation,
these cells secreted high levels of CC chemokines with potent
suppressive activities against CCR5-tropic HIV-1 that could be
blocked by anti-chemokine antibodies. In contrast, MDC,
which is effective against both CCR5- and CXCR4-tropic
HIV, was not produced. Since little and inconsistent suppression
was observed against CXCR4-tropic HIV-1 (data not shown),
we did not analyze other soluble factors known to inhibit
CXCR4-tropic isolates, such as SDF-1 (stromal derived factor
1) and α-defensins. These observations are corroborated by
published reports that CD4+ T cells specific for other antigens
secrete mainly CCR5 ligands and do not suppress CXCR4-
tropic isolates (Lotti et al., 2002; Norris et al., 2004; Robbins et
al., 1998). Interestingly, production of CC-chemokines in the
gp120-specific CD4+ T cells was not accompanied by down-
regulation of cell surface CCR5. Rather, the CCR5 ligands most
likely inhibited virus infection by directly interfering with virus
entry. Studies are now underway to further test this hypothesis
and examine other steps in the virus life cycle that are affected.
The gp120-specific CD4+ T cell lines PS01 and PS02 also
secreted IFN-γ in response to antigen stimulation, but as
compared to the robust and durable CCR5 ligand response,
IFN-γ production was very transient and was observed only in a
small fraction of the cells. Moreover, there is no clear evidence
that IFN-γ mediates direct anti-HIV activities (Creery et al.,
2004; Mackewicz et al., 1994). It should also be noted that
unlike many of the CD4+ T cell lines or clones reported in the
literature (Lotti et al., 2002; Misko et al., 1984; Norris et al.,
2004; Paludan et al., 2002; Robbins et al., 1998), the gp120-
specific CD4+ T cell lines studied here had no cytolytic activity
(Fig. 4D and data not shown). Nevertheless, factors other than
CCR5 ligands might contribute to virus resistance and
suppression in these CD4+ T cells. Of note, decreased HIV
replication has been observed in heterozygous CCR5 Δ32 cells
(Liu et al., 1996). Reduced CCR5 expression due to CCR5/
CCR5 Δ32 heterodimerization has also been reported in T cells
of CCR5 Δ32 heterozygotes and correlated with lower levels of
HIV replication and delayed onset of disease progression inCD4 T cells. Uninfected and BX08-infected PS02 cells were cultured in parallel
ated with peptide pC2 for 6 h and stained with mAbs to p24, IFN-γ, or MIP-1β.
uninfected cells collected on days 1–5. Cells treated with no peptide were also
okine and chemokine. Flow cytometric analyses were performed to measure the
HIV-infected and uninfected PS02 cells stained with mAbs to p24 and IFN-γ.
MIP-1β. (C) Changes in percentages of CD4 T cells positive for p24 and IFN-γ
nfected PS02 cultures.
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et al., 2007). In view of the lower levels of CCR5 expression
and HIV replication in the heterozygous CCR5 Δ32 cells, HIV
infection in these cells may be relatively sensitive to inhibitory
effects of the CCR5 ligands as compared with wild type cells,
but further investigation is necessary to examine this issue.
The capacity of the gp120-specific CD4+ T cells to produce
CCR5 ligands and suppress HIV infection depended on antigen
stimulation prior to or soon after exposure of the cells to the virus
(Figs. 3 and 7). After the cells become infected, the capacity of
these cells to respond to antigen stimulation and produce
chemokines was rapidly abrogated (Fig. 7). These results are
consistent with earlier reports demonstrating that HIV infection
decreases cytotoxicity and cytokine-secreting capacity of CD4+
T cells specific for other pathogens, such as influenza virus and
M. tuberculosis (Robbins et al., 1998; Sutherland et al., 2006). In
our experimental design, there appeared to be a narrow window
of b1 day, where the cells were responsive to antigen stimulation
after virus exposure and almost all cells were still negative for
intracellular p24. However, in this in vitro experiment, a
relatively high dose of virus was used in order to infect the
majority of the cells within 4–5 days. The rates of infection and
spread to virus-specific CD4+ T cells in vivo after human
subjects are exposed to the virus may not necessarily be as rapid.
When rhesus macaques were infected intravaginally with
SIVmac251, SIV RNA-bearing cells rose up only after 8 days of
infection (Li et al., 2005b). We postulate that if virus-specific
CD4+ Tcells that produce CCR5 ligands are recruited within the
initial week to the mucosal sites of primary infection, they will
protect themselves and other CD4+ T cells which would
otherwise succumb to virus infection and become non-
responsive. Therefore, HIV vaccines should include compo-
nents that trigger virus-specific CD4+ T cells to secrete high
levels of these chemokines. Without vaccination, CD4+ T cells
specific for gag and envelope were found in the peripheral blood
of subjects with very early primary HIVinfection (b30 days after
infection or onset of symptoms), but the cells were rapidly lost
thereafter (Malhotra et al., 2003; Zaunders et al., 2005). These
early responses were reported to include CD4+ cytotoxic
effector cells, but the capacity of the cells to secrete CC
chemokines that block entry and infection of the transmitted
viruses was not examined. Nevertheless, it is also possible that
upon virus challenge, production of CC chemokines by HIV-
specific CD4+ T cells may lead to the recruitment of more
inflammatory cells to the mucosal sites of infection, including
dendritic cells that capture HIV via DC-SIGN, independent of
CCR5, thereby facilitating the spread of the virus to the lymph
nodes (Kwon et al., 2002; Sozzani, 2005; Van Montfort et al.,
2007).
This study, together with previous reports, demonstrate that
CD4+ T cells specific for different antigens which can be
stimulated to produce CCR5 chemokines and resist HIV
infection are present in various HIV-infected and uninfected
subjects. Hence, in addition to the CD4+ T cell lines PS01
and PS02 that were derived from HIV+ subjects who were
able to control their virus infection without anti-retroviral
therapy, envelope-specific CD4+ T cell clones secreting veryhigh levels of CCR5 chemokines were also generated from
peripheral blood cells of HIV-exposed uninfected individuals
and of HIV-seronegative subjects immunized with recombi-
nant gp120W61D protein in QS21/MPL adjuvant (Furci et al.,
1997; Jones et al., 1999). A number of gag-specific CD4+ T
cell clones and lines have been generated from acutely and
chronically HIV-infected patients who have received HAART,
and these cells produce CCR5 ligands (Lotti et al., 2002;
Norris et al., 2004, 2001). CD4+ T cells specific for other
antigens, such as tetanus toxoid and influenza virus
hemagglutinin, from HIV-seronegative subjects also showed
the capacity to secrete CCR5 ligands with rapid kinetics, that
would allow for the blocking of HIV entry (Robbins et al.,
1998; Sun et al., 2004). However, one important question that
remains unaddressed is whether HIV-specific CD4 T cells
capable of producing CCR5 ligands constitute a significant
proportion of the CD4 T cell population. Only a subset of the
CD4+ T cell population may produce CCR5 ligands, and
these cells may secrete the chemokines with different kinetics,
as indicated by the observed differences between PS01 and
PS02 lines (Fig. 2). Lotti et al. (2002) also demonstrated that
only a fraction of gag-specific CD4 T cell clones isolated
from the HIV-seropositive subject with the strongest gag-
specific proliferative response in their cohort produced high
levels of MIP-1α and MIP-1β. Hence, one possibility is that a
large proportion of HIV-specific CD4 T cells activated in
response to the infection do not produce CCR5 ligands to a
sufficiently high level and/or with a fast enough rate, and
these cells become exceedingly prone to infection. This would
explain the loss of significant percentages of virus-specific
CD4 T cells and the small numbers that remain uninfected in
most HIV-infected subjects.
Earlier studies of T cell responses in HIV-infected and
uninfected subjects typically measured IFN-γ, IL-2, and/or
TNF-α, but not CCR5 chemokines. Only in late 2006, with the
use of polychromatic flow cytometry, production of MIP-1β
was monitored along with IFN-γ, TNF-α, and IL-2, in CD4+
and CD8+ T cell responses to CMV and HIV, respectively
(Betts et al., 2006; Casazza et al., 2006). It is of interest to note
that MIP-1β production dominated CD8+ T cell responses to
different HIV antigens and was one of the CD8+ T cell
functions that discriminate HIV-infected non-progressors from
progressors (Betts et al., 2006). Whether vigorous production
of CCR5 ligands also characterizes HIV-specific CD4+ T cell
responses in non-progressors as compared to progressors
remains to be determined. It is also not known if high
frequencies of CCR5-ligand-producing T cells are induced by
candidate HIV vaccines that have been tested in pre-clinical
and clinical trials. The parameters used to evaluate T cell
responses to these vaccines typically do not include CCR5
ligands, even though these chemokines directly mediate potent
anti-HIV functions.
The present study shows that CCR5 ligands were secreted by
gp120-specific CD4+ T cells after antigen stimulation. CCR5
chemokine production was much robust and durable as
compared to IFN-γ and IL-2, and importantly, production of
these chemokines led to the suppression of virus infection in
223G. Kaur et al. / Virology 369 (2007) 214–225these cells. These results imply that antigen-driven induction of
HIV-specific CD4+ T cell responses that are accompanied by
secretion of high amounts of CCR5 ligands will provide these
cells some degree of protection from virus infection. Taken
together with the published reports mentioned above, the data
also strengthen the case for including CCR5 ligand production
among the CD4+ T cell responses evaluated in HIV vaccine
trials and in HIV-infected subjects.
Materials and methods
HIV envelope-specific CD4+ T cell lines
Primary CD4+ Tcell lines recognizing epitopes in the C1 and
C2 regions of gp120 were generated from PBMCs of chronically
HIV-1-infected non-progressors PS01 and PS02. PS01 and PS02
have been HIV-seropositive since 1991 and 1985, respectively,
and have maintained HIV RNA loads of b5000 copies/ml and
CD4+ cell counts N600/μl essentially without anti-retroviral
therapy. PS01 received only 8 months of anti-retroviral therapy
prior to 2000, while PS02 never had any anti-retroviral therapy.
Both subjects are heterozygous for the CCR5 Δ32 allele
(unpublished data). All subjects gave informed consent as
required. The study was reviewed and approved by the Veterans
Affairs New York Harbor Healthcare System Institutional
Review Board. The initial characterization of the cell lines
has previously been reported (Cohen et al., 2003). These short-
term cell lines were frozen after the initial 3 or 4 rounds of
antigen stimulation, re-stimulated with gp120 after thawing, and
maintained in cultures for approximately 2 months in complete
RPMI-1640 media supplemented with 10% human AB serum
and 20 U/ml of human recombinant IL-2 (Roche). The cells
were stimulated with gp120 every 2–3 weeks and used in the
experiments 7 or more days after antigen stimulation. Auto-
logous PBMCs were used as antigen-presenting cells for routine
expansion of the cultures. However, in order to measure
chemokines produced specifically by the CD4 Tcells and not by
other cells in the cultures, experiments were set up such that the
CD4 T cells were stimulated with gp120 peptides without
additional antigen-presenting cells. These CD4+ T cells
expressed MHC class II and were capable of presenting
gp120 peptides to one another to elicit production of cytokines
and chemokines as well as proliferation. When contaminating
feeder cells (usually CD8+ cells) were still present in the
cultures, we depleted these cells with antibody-coated magnetic
beads (Dynabeads) to achieve nearly 100% pure population of
CD4+ CD3+ cells. Cytolytic activity of the CD4+ T cells was
assessed in the standard 51Cr release assay using autologous
Epstein Barr virus-transformed B lymphoblastoid cells as target
cells.
Intracellular staining
Intracellular staining to detect production of cytokines and
chemokines in the CD4+ T cell lines was performed as
previously described (Cohen et al., 2003) with minor
modifications. Briefly, CD4+ T cell lines PS01 and PS02 wereincubated with 1 μg/ml of HIV-1 envelope peptides pC1a
(NFNMWKNNMVEQMHEDIISL), pC2 (PKISFEPIPIHYCA-
PAGFAI), an irrelevant envelope peptide (YTTKNIIGTIR-
QAHCNISRA), or no antigen for 8 h. Brefeldin A (10 μg/ml)
was added in the last 6 h of incubation. At the end of the
incubation, the cells were washed, fixed, and stored at −4 °C.
Prior to staining, the cells were permeabilized with BD
FACSPerm solution, and stained with fluorescence-conjugated
antibodies to CD3, CD4 or CD8, IL-2, and IFN-γ or MIP-1β
(BD Bioscience; catalog #: 347344, 340443, 555369, 340448,
340512, 550078). In some experiments, surface CCR5 staining
was also performed on the CD4+ T cell lines treated with the
specific peptides, an irrelevant peptide control, or medium
alone. After 6, 24, and 48 h of antigen stimulation, the cells
were stained with fluorescence-conjugated antibodies to CD3,
CD4, and CCR5 (BD Bioscience catalog #: 347344, 340133,
550856). All flow cytometric experiments were performed
using a BD FACSCalibur flow cytometer and the data were
analyzed using the FlowJo software.
Measurement of chemokines and anti-HIV activity in culture
supernatants
To detect chemokines secreted in the supernatants, the CD4+
T cell lines were either stimulated with their specific peptides or
left untreated, and the supernatants were then collected on the
designated days, frozen at −80 °C, and stored for analyses by
ELISA. Commercial ELISA kits (R&D Systems, Minneapolis,
MN, USA) were used to measure all chemokines.
Assessment of HIV-suppressive activity in supernatants of
the CD4+ T cell lines was done as previously described (Sun et
al., 2004). Briefly, phytohemagglutinin-stimulated PBMCs
from healthy donors were infected with HIV-1BaL (100
TCID50) for 2 h, washed, and then treated with complete
media containing 25% or 50% of the CD4+ T cell supernatants.
For controls, we treated the infected PBMCs with 25% or 50%
of media containing no T cell supernatant. The contribution of
CC chemokines was evaluated by adding a cocktail of
neutralizing polyclonal antibodies to RANTES, MIP-1α,
MIP-1β, and MDC (5 μg/ml each) or isotype-matched control
antibodies (R&D Systems).
HIV-1 infection in antigen-stimulated CD4+ T cell lines
To assess the effects of antigen stimulation on virus
infection, the cells were treated with the specific peptides or
medium alone for 6 h and then infected with varying doses of
HIV-1BX-08 isolate. The virus stock was propagated in
phytohemagglutinin-stimulated PBMCs to yield at least
100 ng p24/ml. Prior to use in the experiments, the virus
particles were centrifuged using the TLA100.3 rotor in the
Beckman Optima MAX ultracentrifuge (43,000 rpm for 1 h at
4 °C) to remove mitogen and other contaminants present in
the virus preparations. The virus pellets were suspended in
fresh medium and used to infect the CD4+ T cells. The
numbers of HIV RNA copies present in the pelleted virus
samples were measured by the branched DNA test (HIV RNA
224 G. Kaur et al. / Virology 369 (2007) 214–2253.0; Bayer). One day after infection, the cells were washed
and cultured with fresh RPMI-1640 medium supplemented
with 10% human AB serum and 20 U/ml of IL-2 (Roche).
Culture supernatants were collected on the designated days
and stored at −80 °C. The concentrations of HIV-1 p24
antigens in the supernatants were measured by non-commer-
cial ELISA.
To detect HIV-infected cells and IFN-γ- orMIP-1β-producing
cells in the cultures, cells were harvested periodically, fixed, and
stained. The previously described intracellular staining protocol
was followed (Cohen et al., 2003), with the exception that
fluorescence-conjugated antibodies to CD3 andCD8were used to
gate the cell population studied and fluorescence-conjugated anti-
p24 monoclonal antibody (KC57; Coulter) was used to detect
virus-infected cells.
Antigen stimulation of HIV-infected CD4+ T cell lines
To assess the effect of HIV infection on envelope-specific
CD4+ T cell responses, the CD4+ T cell lines were first infected
with pelleted stocks of HIV-1BX08 (100 ng p24 per 5×10
6 CD4+
T cells) or left untreated for 24 h. After washing to remove free
virus, the cells were cultured in RPMI 1640 medium with 20%
FCS and IL-2 (20 U/ml; Roche). The infection condition was
optimized in order to infect the majority of the cells within 5
days while the cells remained viable. On the designated days,
the cells were treated with the specific peptides or medium
alone, and stained with fluorescence-conjugated antibodies to
CD3, CD8, p24, and IFN-γ or MIP-1β as described above.
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